Plasma membrane alterations and cytoskeletal changes in apoptosis.
During apoptosis, one of the first membrane changes that can be detected is exposure of phosphatidylserine residues at the outer plasma membrane leaflet, while early apoptosis is also accompanied by changes in the cytoskeletal organization. In this study we investigated the relationship between these two phenomena during olomoucine- and roscovitin-induced apoptosis in human lung cancer and neuroblastoma cell lines. Loss of membrane asymmetry was detected by biotin-labeled or FITC-labeled annexin V binding to negatively charged phosphatidylserine, while cytoskeletal components were visualized by immunocytochemistry. The apoptotic, annexin V-positive, cells were analyzed by flow cytometry, confocal scanning laser microscopy, and Western blotting. We report that cytokeratin and vimentin aggregation in early apoptosis occurs simultaneously with phosphatidylserine exposure and chromatin condensation. In contrast to these intermediate filament proteins, which were disassembled and proteolytically cleaved in early apoptosis, microfilaments and microtubuli were not proteolytically degraded but were found to be present as aggregated filaments in the apoptotic bodies. We also show that loss of membrane asymmetry and cytokeratin aggregation are independent processes, since N-ethylmaleimide-induced phosphatidylserine exposure does not cause cytokeratin disassembly. Vice versa, phorbol 12-myristate 13-acetate-induced cytokeratin filament aggregation does not result in phosphatidylserine exposure.
van Engeland
M
M
Department of Molecular Cell Biology and Genetics, University of Maastricht, The Netherlands.
Kuijpers
H J
HJ
Ramaekers
F C
FC
Reutelingsperger
C P
CP
Schutte
B
B
D000199:Actins / Q000378:metabolism; D017304:Annexin A5; D017209:Apoptosis / Q000502:physiology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology; D002462:Cell Membrane / Q000378:metabolism*; D002843:Chromatin / Q000378:metabolism; D003599:Cytoskeleton / Q000378:metabolism*; D005033:Ethylmaleimide / Q000494:pharmacology; D006801:Humans; D007633:Keratins / Q000378:metabolism; D007701:Kinetin; D008175:Lung Neoplasms / Q000473:pathology; D009447:Neuroblastoma / Q000473:pathology; D010718:Phosphatidylserines / Q000378:metabolism; D011687:Purines / Q000494:pharmacology; D000077546:Roscovitine; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014404:Tubulin / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014746:Vimentin / Q000378:metabolism
D000199:Actins; D017304:Annexin A5; D002843:Chromatin; D010718:Phosphatidylserines; D011687:Purines; D014404:Tubulin; D014746:Vimentin; D000077546:Roscovitine; D007633:Keratins; C090046:olomoucine; D013755:Tetradecanoylphorbol Acetate; D005033:Ethylmaleimide; D007701:Kinetin